Articles
-
Advanced Treatments for Peritoneal Cancer at the Peritoneal Cancer Institute
MoreThe treatment of peritoneal cancer is complex and requires a highly specialized therapeutic approach. For this reason, only a limited number of physicians worldwide perform these procedures. At the Peritoneal Cancer Institute (PCI), a global leader in the field, we offer innovative treatment options tailored to each patient’s individual needs, with the goal of improving […]
-
What is Peritoneal Cancer and How is it Diagnosed?
MorePeritoneal cancer is a rare but serious disease that has a significant impact on those affected. It develops in the peritoneum, a thin membrane that lines and protects abdominal organs such as the stomach, liver and intestines. The disease can appear either as a primary form, originating directly in the peritoneum, or as a secondary […]
-
Barcelona hosts the world’s largest congress on peritoneal cancer
MoreIt is estimated that this disease affects seven people per million inhabitants and accounts for 10% of pelvic cancers. Surgeon Domenico Sabia, director of the Peritoneal Cancer Institute (Teknon Medical Centre in Barcelona), uses two groundbreaking techniques to improve patients’ quality of life. The 15th edition of the PSOGI International Congress on Peritoneal Surface Malignancies […]
-
PIPAC Treatment: Success Rates & Statistics
MorePIPAC Treatment: Success Rates, Statistics, and Everything You Need to Know Peritoneal carcinomatosis, a condition where cancer spreads to the lining of the abdominal cavity, has historically been challenging to treat. However, Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) has emerged as a promising treatment option. This innovative approach has shown encouraging results in improving the quality […]
-
PIPAC: indications and contraindications
MorePIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a medical treatment technique designed to deliver chemotherapy directly to the peritoneal cavity (the area that houses the abdominal organs) in a more targeted manner. It involves the use of an aerosol spray to distribute chemotherapy drugs in the peritoneal space under high pressure. This method aims to improve the effectiveness of chemotherapy for patients with peritoneal carcinomatosis, which initially are not candidates for a complete cytoreductive surgery with HIPEC (CRS+HIPEC).
